Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of E6011 in methotrexate-inadequate responders with rheumatoid arthritis
jRCT2080223385Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of quetmolimab in rheumatoid arthritis (RA) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: ACR20 response rate at Week 12. Started Nov 2016; status: completed.
02
Drugs
quetmolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223385.